ART-treated women with HIV/HCV coinfection have greater deficits in
some structural bone parameters compared to women with HIV only, HCV
only, or neither virus, according to the results of a cross-sectional
study presented at IDWeek 2014 last week in Philadelphia. Among women
with HCV, bone loss was most profound in those with stage 3-4 liver
fibrosis or cirrhosis, which adversely effects bone health.
"Compared to healthy reference participants, the women with HIV/HCV had
decreased tibial trabecular volumetric bone mineral and cortical
thinning, and significant endocortical bone loss, a pattern observed in
other inflammatory diseases," according to Vincent Lo Re of the
University of Pennsylvania, who presented the study findings.
Labels: bone density, Coinfection, Women